Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.78B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.89M
Average 0.82M
Returns on capital
Dianthus Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-32.9%
avg -45.0%
ROIC
-35.5%
avg -46.2%
ROA
-30.6%
avg -39.8%
Analysis
ROA is currently the strongest return metric at -30.6% versus its period average of -39.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Marino Garcia | President, Chief Executive Officer & Director | USD 1.16M | 60 | 65.29K | 0.16% |
Simrat Randhawa | Executive Vice President and Head of R&D | USD 932.68K | 56 | 4.00K | <0.01% |
Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer | USD 786.1K | 37 | 0 | <0.01% |
Judson Taylor | Senior Vice President & Head of Technical Operations | — | — | — | — |
Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. | — | — | — | — |
Adam Veness | Senior Vice President, General Counsel & Secretary | — | 40 | — | — |
Edward G. Carr | Senior VP & Chief Accounting Officer | — | 57 | — | — |
Rashieda Gluck | Head of Clinical Development Operations | — | — | — | — |
Kristina Maximenko | Chief People Officer | — | — | — | — |
Scott Nogi | Head of Business Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
71
$75.05M
Net Transaction Value
−$75.05M
Net selling
Most Active
Savitz Ryan
22 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 12, 26Nov 12, 2026 | Savitz Ryan Direct | Sell | $1.6M$1,605,085.44 |
| Nov 11, 26Nov 11, 2026 | Savitz Ryan Direct | Sell | $274.1K$274,051.32 |
| Nov 10, 26Nov 10, 2026 | Savitz Ryan Direct | Sell | $230.8K$230,848.54 |
| Nov 9, 26Nov 9, 2026 | Savitz Ryan Direct | Sell | $25.5K$25,548.00 |
| Nov 9, 26Nov 9, 2026 | Savitz Ryan Direct | Sell | $5.3M$5,308,196.40 |
| Nov 9, 26Nov 9, 2026 | Savitz Ryan Direct | Sell | $3.4M$3,381,032.04 |
| Nov 9, 26Nov 9, 2026 | Savitz Ryan Direct | Sell | $60.7K$60,690.00 |
| Nov 9, 26Nov 9, 2026 | Savitz Ryan Direct | Sell | $189K$189,041.76 |
| Nov 9, 26Nov 9, 2026 | Savitz Ryan Direct | Sell | $154.2K$154,226.24 |
| Sep 17, 26Sep 17, 2026 | CARR EDWARD Direct | Sell | $113.5K$113,520.00 |
1–10 of 71
Summary
Insiders reported 0 buys worth $0.00 and 71 sells worth $75.05M over the last 12 months. That adds up to net selling of $75.05M. Savitz Ryan was the most active insider with 22 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -31.8% | +219.0% (5yr)12 analysts |
| Net Income | N/A | N/A | N/A | N/A12 analysts |
| EBIT | N/A | N/A | N/A | N/A12 analysts |
Analysis
Recent growth has been strongest in Revenue at -31.8% over three years. Forward estimates point to Revenue at +219.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Dianthus Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about DNTH's management, answered from reported figures.
Who manages DNTH?
Dianthus Therapeutics, Inc. (DNTH) lists 10 active executives. The top listed executive is Judson Taylor, Senior Vice President & Head of Technical Operations.
Are DNTH insiders buying or selling?
Recent insider activity shows net selling of $25.73M.
Continue the stock analysis
Jump to another research area for this company.